Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults age 18 and older compared with its original vaccine, Spikevax.

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

Stephen Fidler is bureau chief at large at The Wall Street Journal in London, a broad-based role that draws on decades of ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Recall the Comirnaty® and Spikevax® mRNA-based vaccines each utilize lipid nanoparticles. The lipid nanoparticles include an mRNA “payload” encapsulated by a combination of four lipids ...

The new vaccine is an updated version of Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS-CoV-2, as well as from the Omicron BA.1 subvariant.

After the success of its COVID-19 vaccine, Spikevax, the company is expanding its pipeline to address other critical areas, such as respiratory vaccines for COVID-19, influenza, and RSV ...

Best known for its COVID-19 vaccine, Spikevax, Moderna also has a broad pipeline targeting respiratory, latent, and enteric viruses, as well as cancer and rare diseases. MRNA is expected to ...